PHC Holdings buys Thermo Fisher’s anatomical pathology division
Category: #health  By Paroma Bhattacharya  Date: 2019-07-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

PHC Holdings buys Thermo Fisher’s anatomical pathology division

PHC Holdings Corporation, a global innovator in healthcare solutions, has reportedly concluded its acquisition of Thermo Fisher Scientific Inc.’s Anatomical Pathology business for approx. US$1.14 billion.

Apparently, the business of Anatomical Pathology will be operating as Epredia, a stand-alone company which will serve as a major provider of comprehensive solutions in the field of anatomical pathology that also includes instruments, consumables and microscope slides.

According to reports, a global healthcare company, PHC Holdings (PHCHD) offers value-added services and products across life sciences, healthcare IT and diabetes care. The acquisition will help PHCHD strengthen its business for diagnostics as it will expand its portfolio into oncology, further supporting the business growth.

President and CEO, PHCHD, Michael Kloss said that the company is looking forward to adding the leading global provider of anatomical pathology solutions to their group. Epredia will provide solutions and high quality products that deliver excellence of precision in cancer diagnostics.

Kloss mentioned that it is a highly successful business, showing a considerable growth and the company believes they can work together and make it more successful by being a part of the PHCHD group.

President of Epredia, James Post commented that the company is looking forward to joining PHCHD group. Despite bearing a new name, Epredia aims to fulfill the same mission, that is to enhance cancer diagnostics for patients and improve lives all over the world. The company has been powered by few key brands like the Menzel, Shandon, Richard Allan and Erie, and the customers have started to appreciate their precision and excellence, Post added.

Kloss further explained that the acquisition is essential for PHCHD group because the company sees a major potential for growth in the business and foresees opportunities for synergies with the existing business segment. This is an important step ahead for the group to continue to build a healthcare company that contributes to the health of the society and eventually improve lives. Kloss added.

Source Credit-  https://www.phchd.com/global/news/2019/0629



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...